Investors and states have ploughed capex into new proton therapy machines across Europe as the machines get smaller, the range of use cases grows and more private insurers start to cover the therapy.
French real estate investor Icade, has set a price range of €115-135 per share for the upcoming IPO of Icade Sante, its healthcare property business. This values it at up to €6.4bn.
Potential winners of Germany's upcoming elections are pledging to abolish private medical insurance (PKV). The move could spell disaster for the whole healthcare sector: it accounts for 37% of all expenditure.
European countries will spend about €50bn on healthcare infrastructure spending thanks to loans and grants from the EU. However, we are months down the line and it's still not clear how the for-profit will benefit. Some operators are also worried that a flood of public sector capex spending will make them less competitive.
There were strong opinions at HBI 2020 on the key question as to whether NHS activity in the UK will ever return to pre-pandemic levels; UK CEOs and investors at HBI 2021 were less than optimistic about its chances, but double digit private growth is filling the gap.
The Swedish government proposed a new budget totalling €7.3bn (SEK74bn) to the parliament, Riksdag, on Monday (September 20). Roughly SEK2.5bn (€247m) is being allocated to elderly care to help the sector recover from COVID. Despite improvements, HBI hears lack of level-playing field between municipalities remains a real struggle.
The direct-to-consumer or B2C diagnostics sector began well before Covid. Over the past decade, increasing numbers of people have used at-home testing kits to screen for a variety of diseases (cancers, cardiac diseases and STIs), as well as to evaluate genetic susceptibility and find out about their ancestry.
